Click on these pictures to learn more about Curemark's pipeline.
Curemark is a pioneering, research-driven biotechnology company that develops and markets innovative products to fulfill needs in neurological medicine. The company is committed to improving the quality of life for children and adults with neurological disorders by providing safe, effective and clinically proven solutions. The company’s flagship product is focused on treating children with autism. Curemark’s breakthrough product is based on proprietary technology developed by the company’s CEO and founder, Dr. Joan Fallon.
Curemark is focused on the treatment of neurological and other diseases by addressing certain pancreatic secretory deficiencies. These deficiencies are thought to play a key role in neurological disorders by altering the availability and absorption of key amino acids, affecting various organ systems and neurological function.
With recent understanding that dysautonomia, or a major malfunction of the autonomic nervous system, may underlie multiple disease processes, Curemark's patent portfolio is designed to address many of the major dysautonomic conditions, including familial dysautonomia and Parkinson's disease.